论文部分内容阅读
目的：观察生脉散注射液与黄芪注射液对冠心病伴左心功能不全（ＬＶＤ）的疗效比较。方法：冠心病伴ＬＶＤ５１例。生脉散组３２例，给生脉散注射液８支（１０ｍＬ／支）加入１０％葡萄糖注射液５００ｍＬ静脉滴注（静滴），ｑｄ；黄芪对照组１９例，应用黄芪注射液６支（２ｍＬ／支）加入１０％葡萄糖注射液５００ｍＬ静滴，ｑｄ，２组均用药１４ｄ。结果：生脉散不仅能改善左室收缩功能（ＳＶ，ＣＯ，ＣＩ，ＦＳ，ＥＦ）（Ｐ＜０．０１），对舒张功能也有显著的疗效（ＰＥ，ＥＳ，ＰＥ／ＰＡ）（Ｐ＜０．０１）。临床无明显不良反应。而黄芪注射液仅对左心收缩功能（ＣＯ，ＣＩ，ＦＳ，ＥＦ）有改善（Ｐ＜０．０１或Ｐ＜０．０５）。结论：生脉散注射液治疗冠心病伴ＬＶＤ疗效优于黄芪注射液。
Objective: To observe the effect of Shengmansan injection and Astragalus injection on coronary heart disease with left ventricular dysfunction (LVD). Methods: Coronary heart disease with LVD in 51 cases. Shengmai powder group 32 cases, Shengmaisan injection 8 (10mL / branch) by adding 10% glucose injection 500mL intravenous drip (qd; qd; astragalus control group 19 cases, the application of Astragalus injection 6 2mL / support) added 10% glucose injection 500mL intravenous infusion, qd, two groups were medication 14d. Results: Shengmai Powder can not only improve left ventricular systolic function (SV, CO, CI, FS, EF), but also have significant effects on diastolic function (PE, ES and PE / PA) 0.01). No obvious clinical adverse reactions. Astragalus injection only improved left ventricular systolic function (CO, CI, FS, EF) (P <0.01 or P <0.05). Conclusion: Shengmansan injection in treatment of coronary heart disease with LVD is superior to Astragalus injection.